Galderma Laboratories has agreed to a $990,000 settlement to resolve a class action lawsuit alleging that certain Differin branded benzoyl peroxide acne treatments were potentially contaminated with benzene, a well known carcinogen. The settlement received preliminary court approval on February 19, 2026, and covers consumers who purchased the affected products in the United States between January 1, 2020, and February 19, 2026.
Which Products Are Covered
Three Differin branded products are included in the settlement:
- Differin Daily Deep Cleanser (5% Benzoyl Peroxide)
- Differin Acne Spot Treatment (10% Benzoyl Peroxide)
- Differin Maximum Strength Acne Foaming Cleanser (10% Benzoyl Peroxide)
The lawsuit, filed as Williams v. Galderma Laboratories, L.P. in the Northern District of Illinois, alleged that Galderma failed to warn consumers that these products may have been contaminated with benzene and misled buyers about the safety of the treatments they were purchasing.
What Affected Consumers Can Claim
Class members who submit a valid and timely claim are eligible to receive $9 in reimbursement for each covered product purchased. There is no limit on the number of products a class member may claim with proof of purchase, though claims submitted without proof of purchase are capped at three products per household. Payouts may be subject to pro rated adjustments depending on the total number of valid claims filed. All claim forms must be submitted online or by mail by May 19, 2026, with a final approval hearing scheduled for June 30, 2026.
The Broader Benzene Contamination Issue in Beauty
The Galderma settlement is part of a wider wave of litigation targeting benzene contamination in personal care and skincare products. Benzene is a known human carcinogen with no safe level of exposure, and its presence in consumer products has triggered class actions against multiple brands across the beauty and personal care industry in recent years. Independent lab testing organizations, including Valisure, have been instrumental in identifying benzene contamination in products ranging from sunscreens to acne treatments, forcing manufacturers to respond. For consumers, the case is a reminder that even trusted, clinically positioned brands are not immune to contamination risks that can arise at the formulation or storage stage.
Lessons for Brands to Avoid
The Galderma settlement is a signal to the entire beauty and personal care industry that ingredient safety cannot be treated as a back office compliance matter. As independent testing becomes more accessible and class action litigation more sophisticated, brands face growing legal and reputational exposure from contamination risks that were previously unlikely to surface publicly.
- Independent testing is no longer optional. The rise of third party lab organizations actively testing consumer products means brands can no longer rely solely on internal quality control. Proactive independent testing for known contaminants like benzene should be a standard part of any personal care brand’s product safety protocol.
- Failing to disclose known risks compounds the legal exposure. The lawsuit alleged not just contamination but a failure to warn consumers. In class action litigation, the concealment of a known risk almost always results in more severe legal and reputational consequences than the underlying issue itself.
- Benzoyl peroxide formulations carry specific stability risks. Research has shown that benzoyl peroxide can degrade into benzene under certain temperature and storage conditions. Brands formulating with BPO at any concentration should be investing in stability testing across a range of real world conditions, not just controlled laboratory environments.
- A settlement is not the end of the reputational story. For a clinically positioned brand like Differin, the association between its acne treatments and a known carcinogen will outlast the legal resolution. Brands need to pair any settlement with clear, proactive consumer communication about the corrective steps taken.
